Hubungan Jenis Kemoterapi Terhadap Kejadian Chemotherapy Induced Peripheral Neuropathy (CIPN) Pada Pasien Kanker Di Rsud Abdul Moeloek Bandar Lampung

Wiwin Wildaniatul Janah, Sariningsih Sariningsih, Sandhy Arya Pratama, Raden ayu Neilan Amroisa

Sari


Kemoterapi merupakan salah satu modalitas utama dalam penatalaksanaan kanker, namun penggunaannya sering menimbulkan efek samping, salah satunya chemotherapy-induced peripheral neuropathy (CIPN), yang dapat menurunkan kualitas hidup serta mengganggu keberlanjutan terapi. Kejadian CIPN bervariasi dan dipengaruhi oleh jenis agen kemoterapi yang digunakan. Penelitian ini bertujuan untuk mengetahui hubungan antara jenis kemoterapi dengan kejadian CIPN pada pasien kanker di RSUD Abdul Moeloek tahun 2025. Penelitian ini merupakan studi analitik dengan pendekatan cross sectional terhadap 78 pasien kanker yang menjalani kemoterapi. Analisis statistik menggunakan uji Chi-square untuk menilai hubungan antara jenis kemoterapi dan kejadian CIPN. Hasil penelitian menunjukkan sebagian besar pasien berusia 46–59 tahun (53,8%), berjenis kelamin perempuan (75,6%), dan didominasi oleh kanker payudara (52,6%). Mayoritas pasien menerima kombinasi kemoterapi neurotoksik dan non-neurotoksik (52,6%), dengan kejadian CIPN terbanyak pada kategori ringan (84,6%). Uji Chi-square menunjukkan adanya hubungan yang signifikan antara jenis kemoterapi dan kejadian CIPN (p = 0,002). Dengan demikian, dapat disimpulkan bahwa terdapat hubungan yang bermakna antara jenis kemoterapi dan kejadian CIPN pada pasien kanker di RSUD Abdul Moeloek Bandar Lampung tahun 2025.


Kata Kunci


Kemoterapi, Jenis Kemoterapi; CIPN; Kanker; Neuropati Perifer

Teks Lengkap:

PDF

Referensi


Ambarwati, W.N. and Wardani, E.K. (2014) Efek samping kemoterapi secara fisik pasien penderita kanker servik. Prosiding Seminar Nasional & Internasional, 2(2).

American Cancer Society (2019) Chemotherapy to Treat Cancer. Available at: https://www.cancer.gov/about-cancer/treatment/types/chemotherapy (Accessed: 14 October 2025).

American Cancer Society (2019) Types of Chemotherapy Drugs. Available at: https://www.cancer.org/cancer/managing-cancer/treatment types/chemotherapy/types-of-chemo-drugs.html (Accessed: 14 October 2025).

American Cancer Society (2024) What is Chemotherapy? Available at: https://www.cancer.org/cancer/managing-cancer/treatment types/chemotherapy.html (Accessed: 14 October 2025).

Anvi, N. M. (2024) Gambaran Chemotherapy-induced Peripheral Neuropathy pada pasien kanker yang menjalani kemoterapi Taxane. Skripsi. Fakultas kedokteran universitas andalas.

Apriadi, D., Susmiati, S. and Gusty, R.P. (2021) Perbandingan Akupresur Satu Lengan dan Dua Lengan pada Titik PC6 terhadap Mual Muntah pada Penderita Ca Mammae yang Menjalani Kemoterapi, Jurnal Ilmiah Permas, 11(3), pp. 531–540.

Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L. and Jemal, A. (2024) Global cancer statistics 2022, CA: A Cancer Journal for Clinicians, 74(3), pp. 229–263. https://doi.org/10.3322/caac.21834 (Accessed: 14 October 2025).

Burgess, J., et al. (2021) Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment, Neurology and Therapy. https://doi.org/10.1007/s40120-021-00282-8

Colvin, L.A., et al. (2019) Chemotherapy-induced peripheral neuropathy: Where are we now?’, Pain, 163(Suppl 1), pp. S1–S10. https://doi.org/10.1097/j.pain.0000000000002643 (Accessed: 14 October 2025).

Danil, N. et al. (2023) Perbandingan respon terapi dan toksisitas regimen kemoterapi kombinasi antara paclitaxel, carboplatin, dan ifosfamide (TIP) dengan paclitaxel dan carboplatin (TP) pada kanker serviks stadium IIB, Indonesian journal of obstetrics & gynecology science, 6(1),pp.82-88.

Desforges, M., et al. (2022) Chemotherapy-induced peripheral neuropathy: pathophysiology and therapeutic perspectives’, Frontiers in Pain Research, 3, 890978.

https://doi.org/10.3389/fpain.2022.890978 (Accessed: 14 October 2025).

Dinas Kesehatan Provinsi Lampung. (2022). Profil Kesehatan Provinsi Lampung Tahun 2021. Bandar Lampung: Dinkes Provinsi Lampung.

Fehrenbacher, J.C. (2015) Chemotherapy-induced peripheral neuropathy, Progress in Molecular Biology and Translational Science, 131, pp. 471–508.

Hanun, K.N. (2024) Faktor-faktor yang berhubungan dengan kepatuhan kemoterapi pasien kanker payudara. Poltekkes Kemenkes Tanjungkarang.

Haroen, H. and Gimon, I. (2024) Hubungan Jenis dan Siklus Kemoterapi dengan Derajat Neuropati, Jurnal Abdi Insani, 11(1), pp. 173–183.

Hou, S., et al. (2018) Treatment of Chemotherapy-Induced Peripheral Neuropathy, Pain Physician, 21(6), pp. 571–592.

Janvagrith (2021) Neuropati perifer pada penyintas kanker ovarium di RSUP Haji Adam Malik. Medan: RSUP Haji Adam Malik.

Jordan, B., et al. (2020) Systemic anticancer therapy-induced neurotoxicity, Annals of Oncology, 31(10), pp. 1306–1319.

Jordan, B., et al. (2023) ESMO Clinical Practice Guidelines: Systemic anticancer therapy-induced peripheral and central neurotoxicity’, Annals of Oncology, 34(6), pp. 533–548.

https://doi.org/10.1016/j.annonc.2023.03.006 (Accessed: 14 Januari 2026).

Kementerian Kesehatan Republik Indonesia (2014) Panduan Penatalaksanaan Kanker Payudara. Jakarta.

Kementerian Kesehatan Republik Indonesia (2023) Profil Kesehatan Indonesia Tahun 2022. Jakarta. Available at: https://pusdatin.kemkes.go.id

Lee, K.T., et al. (2024) Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Narrative Review’, Cancers, 16(14), 2571.

Li, T., et al. (2022) Assessing chemotherapy-induced peripheral neuropathy, Supportive Care in Cancer, 30(11), pp. 9205–9215.

Loprinzi, C.L., et al. (2020) Prevention and management of chemotherapy-induced peripheral neuropathy, Journal of Clinical Oncology, 38(28), pp. 3325–3348. https://doi.org/10.1200/JCO.20.01399

Mattar, M., et al. (2024) Neuropati Perifer yang Diinduksi Kemoterapi, Life, 14(8), 991.

Molassiotis, A., et al. (2021) Chemotherapy-induced peripheral neuropathy in cancer survivors, Supportive Care in Cancer, 29(2), pp. 623–632.

National Cancer Institute (2021) Chemotherapy to Treat Cancer. Available at: https://www.cancer.gov

Ostios-Garcia, L., et al. (2024) Classification of anticancer drugs, Cancer and Metastasis Reviews, 43(4), pp. 1561–1571.

Oyekan, E., et al. (2024) Chemotherapy-induced peripheral neuropathy among breast cancer patients, Supportive Care in Cancer.

Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., Hoang-Xuan, K., Lantéri-Minet, M., Grant, R., & Huddart, R. (2005). The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer, 41(8), 1135–1139. https://doi.org/10.1016/j.ejca.2005.02.012

Rahman, N., Sukumar, J. and Lustberg, M.B. (2025) Chronic chemotherapy-induced peripheral neuropathy, Annals of Palliative Medicine, 14(2), pp. 196–216.

Rumastika, N.S. (2016) Kemoterapi pada Penyakit Kanker. Yogyakarta: FK UGM.

Seretny, M., et al. (2014) Incidence, prevalence, and predictors of chemotherapy- induced peripheral neuropathy, Pain, 155(12), pp. 2461–2470.

Setyobudi, Y.E. and Sakti, I.P. (2024) Chemotherapy-related side effects and self-concept, Al-Hikmah Nursing and Health Journal, 3(1), pp. 34–41.

Soejitno, A. and Widyadharma, I.P.E. (2024) Chemotherapy-induced peripheral neuropathy biomarkers, Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 60(1), 92.

Starobova, H. and Vetter, I. (2017) Pathophysiology of chemotherapy-induced peripheral neuropathy, Nature Reviews Neurology, 19(5), pp. 299–315.

Sung, H., et al. (2022). Global patterns in cancer incidence and mortality. CA: A Cancer Journal for Clinicians.

Van Haren, F., et al. (2022) Diagnostic tools for chemotherapy-induced peripheral neuropathy, Cancer Reports, 5(10), e1577




DOI: https://doi.org/10.33024/jikk.v13i8.25481

Refbacks

  • Saat ini tidak ada refbacks.


##submission.copyrightStatement##

##submission.license.cc.by-nc4.footer##

Pendidikan Dokter Universitas Malahayati Lampung


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.